LITTLE ROCK — Arkansas’ Medicaid program will receive nearly $490,000 from a settlement in a lawsuit that alleged a pharmaceutical company paid kickbacks and improperly marketed four of its drugs, Attorney General Dustin McDaniel said Friday.

Connecticut-based Boehringer Ingelheim Pharmaceuticals Inc. agreed to pay Arkansas, other states and the federal government a total of $95 million to resolve the lawsuit, which was filed over the company’s marketing of the drugs Atrovent, Combivent, Micardis and Aggrenox.

The lawsuit alleged that the company marketed the drugs for a variety of non-FDA-approved illnesses, thereby causing false claims to be submitted to Medicaid. Additionally, the settlement resolves allegations that the company paid kickbacks to health care professionals as an inducement to prescribe.

A phone message left for a spokeswoman for Boehringer Ingelheim was not immediately returned Friday.